Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cardiologists who Implant Epic HF Implantable Cardioverter Defibrillators (US)

Articles with lock require a subscription to GLG News | Request a free trial
Brian OlshanskyMarch 5, 2008
The Future of Stereotaxis
Analysis of: Stereotaxis shares tank on Q4 loss | www.24x7mag.com
Author: Brian Olshansky, Professor of Medicine, University of Iowa Hospitals and Clinics
The development of the new technology related to Stereotaxis has been slow going.  While there is much hope there is also much hype.  It is not clear that Stereotaxis really adds much to the success of catheter ablation of atrial fibrillaiton.  There has been a vocal minority...
Daniel WeissOctober 18, 2007
Medtronic - the new Guidant?
Analysis of: Medtronic Pulls Heart Device Wires | www.thestreet.com
Author: Daniel Weiss, Chief Medical Officer, Vicor Technologies, Inc.
The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?
October 17, 2007
Another ICD Related Recall - The Medtronic Fidelis ICD Lead: Increase in Fractures
Analysis of: Patients Warned as Maker Halts Sale of Heart Implant Part | www.nytimes.com
Author: GLG Expert Contributor
With the industry still struggling to recover from the relatively recent Guidant ICD recalls it is possible that this latest ICD lead recall will affect overall ICD implant rates.  It is also possible that Medtronic, the leader in the ICD market, will suffer a loss of market share due to this latest...
Daniel WeissSeptember 17, 2007
TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement
Analysis of: ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com
Author: Daniel Weiss, Chief Medical Officer, Vicor Technologies, Inc.
TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.
August 28, 2007
Medical Tourism
Analysis of: American's Gamble for Bargain Surgery Abroad | www.medpagetoday.com
Author: GLG Expert Contributor
Medical Tourism is purely linked to lower costs for the same procedure.Most of these relate to 1)Small elective surgeries 2) Non-Urgent Cardiac and Non-Cardiac Procedures and Operations 3)Cosmetic Procedures 4)Dental and Vision corrective procedures 5)Radiologic Procedures(Diagnostic and Ther...
August 28, 2007
Angio-seal today-SS
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
Author: GLG Expert Contributor
The key implications remain 1)Safety 2)Efficacy 3)Cost 4)Complications e)Outcome analysis
May 11, 2007
remote monitoring will assist with tele-medicine in the field of arrhythmias
Analysis of: Remote Patient Monitoring and Disease Management Solutions Key to Promoting Growth in U.S. Tele-Health Solutions Market | sev.prnewswire.com
Author: GLG Expert Contributor
Remote monitoring is one of the most important areas of development in the field of cardiac arrhythmias and will play an important role in the field of tele-medicine. The applies to the cardiac rhythm management market as well as the diagnostic market. In the field of cardiac rhythm management, all...
May 1, 2007
TRA assessment
Analysis of: Schering-Plough Announces Initiation Of Two Phase III Clinical Trials For Novel Selective Antiplatelet Therapy (TRA-SCH 530348) | www.medicalnewstoday.com
Author: GLG Expert Contributor
Three key points1) Large unmet need2) Need to assess efficacy against current available treatment3) Safety issues need to be clarified.
March 30, 2007
Predicting sudden death risk with T-wave alternans testing: The ALPHA study reported at the 2007 ACC meeting
Analysis of: Prognostic Value of T-Wave Alternans in Patients with Heart Failure Due to Nonischemic Cardiomyopathy: Results of the T-Wave Alternans in Patients wit | acc07.acc.org
Author: GLG Expert Contributor
 The Prognostic Value of T-Wave Alternans in Patients with Heart Failure Due to Nonischemic Cardiomyopathy: Results of the T-Wave Alternans in Patients with Heart Failure (ALPHA) Study demonstrative a high negative predictive value for sudden cardiac death in patients with non-ischemic cardiomyopathy...
March 26, 2007
A lot of fuss about nothing
Analysis of: St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device with AF Suppression Technology | salesandmarketingnetwork.com
Author: GLG Expert Contributor
1. This technology has been in SJM pacemakers for long enough that we know AF is not eliminated - merely reduced in amount2. Reduction in AF burden does not translate into reduced need for anticoagulation in this high risk population3. Reduction in AF burden does not translate into reduction in...

Page : 1 2 Next1 to 10 of 12

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773